Thalidomide-Piperazine-PEG1-COOH
|
|
2731007-11-5
|
Pomalidomide-PEG4-C-COOH
|
E3 Ligase Ligand-Linker Conjugates 1
|
2097938-44-6
|
MRT00033659
|
|
1401731-54-1
|
GSK682753A
|
1334294-76-6
|
1334294-76-6
|
ML401
|
|
1597489-14-9
|
NIBR189
|
|
1599432-08-2
|
EAI045
|
EAI-045
|
1942114-09-1
|
EAI001
|
2-(1-氧代異吲哚啉-2-基)-2-苯基-N-(噻唑-2-基)乙酰胺
|
892772-75-7
|
ARRY-380 analog
|
ARRY-380
|
937265-83-3
|
TAS0728
|
|
2088323-16-2
|
Zipalertinib
|
齊帕勒替尼
|
1661854-97-2
|
Alflutinib mesylate
|
AST2818甲磺酸鹽
|
2130958-55-1
|
JND3229
|
|
2260886-64-2
|
Gefitinib-based PROTAC 3
|
|
2230821-27-7
|
Nazartinib
|
EGF816
|
1508250-71-2
|
EGFR-IN-11
|
|
2463200-44-2
|
AZ7550 Mesylate
|
|
2319837-99-3
|
CP-724714
|
2-甲氧基-N-[3-[4-[[3-甲基-4-[(6-甲基-3-吡啶基)氧基]苯基]氨基]-6-喹唑啉基]-2-丙烯-1-基]乙酰胺
|
537705-08-1
|
BMS-690514
|
(3R,4R)-4-氨基-1-[[4-[(3-甲氧基苯基)氨基]吡咯并[2,1-F][1,2,4]三嗪-5-基]甲基]哌啶-3-醇
|
859853-30-8
|
PD153035 hydrochloride
|
4-[(3-溴苯基)氨基]-6,7-二甲氧基喹啉
|
153436-54-5
|
AG-1478
|
AG1478
|
153436-53-4
|
AST-1306
|
|
897383-62-9
|
Mutant EGFR inhibitor
|
N-[5-[[5-氯-4-(1H-吲哚-3-基)-2-嘧啶基]氨基]-2-[[2-(二甲基氨基)乙基]甲基氨基]-4-甲氧基苯基]-2-丙烯酰胺
|
1421373-62-7
|
AZD-9291 (Mesylate)
|
AZD9291(甲磺酸鹽)
|
1421373-66-1
|
Thalidomide-piperazine-Boc
|
1-Piperazinecarboxylic acid, 4-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-, 1,1-dimethylethyl ester
|
2222114-64-7
|
Simotinib
|
|
944258-89-3
|
Lazertinib
|
拉澤替尼布
|
1903008-80-9
|
Thalidomide 4'-ether-alkylC2-amine hydrochloride
|
Thalidomide-linker 6
|
2341840-99-9
|
Thalidomide-NH-PEG3-propionic acid
|
Pomalidomide-PEG3-CO2H
|
2138440-82-9
|
HLM006474
|
CS-1224
|
353519-63-8
|
PD168393
|
|
194423-15-9
|
(S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride
|
(S,R,S)-AHPC-PHENOL-C4-NH2 (DIHYDROCHLORIDE)
|
2376990-26-8
|
Lapatinib ditosylate monohydrate
|
二對甲苯磺酸拉帕替尼一水合物
|
388082-78-8
|
(E/Z)-AG490
|
酪氨酸磷酸化抑制劑AG490
|
134036-52-5
|
Almonertinib mesylate
|
阿美替尼甲磺酸鹽
|
2134096-06-1
|
Antiviral agent 24
|
N6-(3-Trifluoromethylbenzyl)adenosine
|
23661-03-2
|
123C4
|
化合物123C4
|
2034159-30-1
|
MB05032
|
2-氨基-5-異丁基-4-[5-膦?;?2-呋喃基]噻唑
|
261365-11-1
|
Linagliptin
|
利拉利汀
|
668270-12-0
|
FIN56
|
|
1083162-61-1
|
iFSP1
|
1-amino-3-(4-methylphenyl)pyrido[1,2-a]benzimidazole-2,4-dicarbonitrile
|
150651-39-1
|
GPX4-IN-3
|
化合物 GPX4-IN-3
|
2761004-85-5
|
Pifithrin-β hydrobromide
|
環(huán)狀抑制劑-Α氫溴酸鹽
|
511296-88-1
|
NADPH tetrasodium salt
|
還原型輔酶Ⅱ四鈉
|
2646-71-1
|
Eugenol-d3
|
|
1335401-17-6
|
Alogliptin-d3
|
|
1133421-35-8
|
Setanaxib
|
2-(2-氯苯基)-4-[3-(二甲基氨基)苯基]-5-甲基-1H-吡唑并[4,3-C]吡啶-3,6(2H,5H)-二酮
|
1218942-37-0
|
OSI-420 free base
|
2-[[4-[(3-乙炔基苯基)氨基]-7-(2-甲氧基乙氧基)-6-喹唑啉基]氧基]乙醇
|
183321-86-0
|
AZD3759
|
|
1626387-80-1
|
RG 13022
|
RG-13022
|
136831-48-6
|
Compound 56
|
N-(3-溴苯基)-6,7-二乙氧基-4-喹唑啉胺
|
171745-13-4
|
Pleconaril
|
普可那利
|
153168-05-9
|
Erastin2
|
4(3H)-Quinazolinone, 2-[[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]methyl]-3-[4-(1-methylethoxy)[1,1'-biphenyl]-3-yl]-
|
1695533-44-8
|
AR-9281
|
1-[(1-Acetylpiperidin-4-yl)-3-adamantan-1-yl]urea
|
913548-29-5
|
AP-III-a4
|
|
1177827-73-4
|
Golgicide A-2
|
|
1394285-50-7
|
Rupintrivir
|
(2E,4S)-4-[(2R,5S)-2-(4-氟芐基)-6-甲基-5-(5-甲基異惡唑-3-基甲酰氨基)-4-氧代庚酰氨基]-5-[[(3S)-2-氧代-3-吡咯烷基]-2-戊烯酸乙酯
|
223537-30-2
|
Pirodavir
|
吡羅達韋
|
124436-59-5
|
UAMC-3203 hydrochloride
|
|
2271358-65-5
|
Pioglitazone-d4
|
匹格列酮-D4
|
1134163-29-3
|
Deferasirox
|
地拉羅司
|
201530-41-8
|
ONO-AE3-208
|
4-氰基-2-[[2-(4-氟-1-萘基)-1-氧代丙基]氨基]苯基丁酸
|
402473-54-5
|
Pioglitazone
|
匹格列酮
|
111025-46-8
|
Dopamine-d5 (hydrochloride)
|
鹽酸多巴胺:(2 - (3 4-DIHYDROXYPHENYL)
|
2193106-55-5
|
Ifebemtinib
|
Ifebemtinib (BI-853520)
|
1227948-82-4
|
BI-4464
|
BI 4464)
|
1227948-02-8
|
GSK215
|
|
2743427-26-9
|
PND-1186
|
PND1186
|
1061353-68-1
|
sEH inhibitor-7
|
化合物 SEH INHIBITOR-7
|
340221-20-7
|
GSK2256294A
|
SEH抑制劑(GSK2256294A)
|
1142090-23-0
|
JWG-071
|
|
2250323-50-1
|
BAY885
|
BAY-885
|
2307249-33-6
|
FAPI-46
|
|
2374782-04-2
|
FAPI-34
|
|
2374782-07-5
|
FAP-2286
|
FAP2286
|
2581741-18-4
|
KO-947
|
|
1695533-89-1
|
FR 180204
|
FR180204
|
865362-74-9
|
ASTX029
|
ASTX-029
|
2095719-92-7
|
Anti-inflammatory agent 35
|
化合物T64358
|
2293951-00-3
|
RLX-33
|
|
2784577-71-3
|
Ravoxertinib
|
GDC-0994
|
1453848-26-4
|
Ulixertinib (hydrochloride)
|
BVD-523 鹽酸鹽
|
1956366-10-1
|
DY131
|
N'-(4-(二乙氨基)亞芐基)-4-羥基苯甲酰肼
|
95167-41-2
|
URB597
|
|
546141-08-6
|
BMS-962212
|
|
1430114-34-3
|
Edoxaban tosylate
|
伊多塞班對甲苯磺酸鹽
|
480449-71-6
|
Ozagrel
|
奧扎格雷
|
82571-53-7
|
ERK1/2 inhibitor 1
|
|
2095719-90-5
|
Darexaban
|
N-[2-羥基-6-(4-甲氧基苯甲酰氨基)苯基]-4-(4-甲基-1,4-二氮雜庚烷-1-基)苯甲酰胺
|
365462-23-3
|
(rel)-AR234960
|
|
1408311-94-3
|
Lidocaine
|
利多卡因
|
137-58-6
|
BI-3663
|
|
2341740-84-7
|
Defactinib
|
地法替尼
|
1073154-85-4
|
BIX02188
|
(3Z)-3-[[[3-[(二甲基氨基)甲基]苯基]氨基]苯亞甲基]-2,3-二氫-2-氧代-1H-吲哚-6-甲酰胺
|
334949-59-6
|
XMD17-109
|
XMD17 109
|
1435488-37-1
|
Asundexian
|
|
2064121-65-7
|
GSK2256098
|
GSK-2256098
|
1224887-10-8
|
Conteltinib
|
|
1384860-29-0
|
Tizaterkib
|
CS-2696
|
2097416-76-5
|
LM22B-10
|
2-[[4-[[4-[BIS-(2-HYDROXYETHYL)-AMINO]-PHENYL]-(4-CHLORO-PHENYL)-METHYL]-PHENYL]-(2-HYDROXY-ETHYL)-AMINO]-ETHANOL
|
342777-54-2
|